Giant breed dogs: 1-5 years of age
Large breed dogs: 1-7 years of age
Small breed dogs: 1-10 years of age
Vaccine
Booster Recommendation
Comments
CORE VACCINES
Parvovirus*
After 1-yr and then every 3-yr
Included in DAPPV/3-yr DAPV
After 1-yr and then every 3-yr
Included in DAPPV/3-yr DAPV
ADDITIONAL VACCINES
Annually
Because all dogs are at risk due to predation or exposure to environmental contamination, vaccine is recommended for all
*Repeat once 3-4 weeks after initial vaccine if not appropriately boosted as puppy
Service Provided
Product / Service Info
Medical Services
Physical Examination
Nail Trim
Maintenance
Anal Sac Expression
Maintenance
Immunization
Rabies 3-years vaccine
VANGUARD RABIES 3 YEAR (Zoetis)
NOBIVAC 3-RABIES (Merck)
IMRAB 3 TF (BI)
RAB VAC 3 (Elanco)
DAPV 3-years vaccine
NOBIVAC CANINE 3-DAPV (Merck)
Bordetella/Parainfluenza combo vaccine
NOBIVAC Intra-Trac Oral BbPi (Merck)
Leptospirosis vaccine
LEPTOVAX 4 (Elanco)
RECOMBITEK 4 LEPTO (BI)
NOBIVAC LEPTO4 (Merck)
VANGUARD L4 LEPTO (Zoetis)
Bivalent Influenza Vaccine
VANGUARD CIV H3N2 H3N8 (Zoetis)
Lyme Vaccine
Diagnostics
Adult Annual with Fecal Dx® Profile andLab 4Dx® Plus Test (38749999)
Chem 18 with IDEXX SDMA® Test, IDEXX CBC®,fecal ova and parasites, hookworm, roundworm and whipworm antigen immunoassays, Lab4Dx® Plus Test
AFAST/TFAST Wellness Ultrasound scan(Package Deal)
*Ultrasound-guided cystocentesis also performed during routine AFAST for routine urinalysis included in IDEXX profile
Preventatives
Interceptor plus
1 dose administered/provided
Simparica Trio Chewable Tablets
6 month supply provided
Dental Chews
CET Chews
Other available vaccines:
VACCINE
PRODUCT INFO
Rabies 1-year vaccine
IMRAB 1 (BI)
RABVAC 1 RABIES VACCINE (Elanco)
NOBIVAC RABIES 1 (Merck)
VANGUARD RABIES 1 (Zoetis)
DA2PP + Leptospirosis vaccine combo
ULTRA DURAMUNE DAP PLUS 4L (Elanco; SQ)
VANGUARD DAPP/L4 (Zoetis; SQ)
NOBIVAC CANINE 1-DAPPV PLUS L4 (Merck; SQ)
Bordetella
Tier 1: Intranasal
VANGUARD® RAPID RESP 3 (Zoetis)
NOBIVAC INTRA-TRAC3 (Merck)
BRONCHI-SHIELD III (Elanco)
Recombitek KC2 Vaccine (BI)
Tier 2: Parenteral
VANGUARD® B INJECTABLE (Zoetis)
HealthChek™ with Fecal Dx® Profile, Lab 4Dx® Plus and Urinalysis (89369999) covers the necessary elements for early detection and prevention of common diseases, and thus the recommended test by The Vets Internal Medicine expert, Dr. Andrea Johnston. Possible alternatives are outlined below.
Test Name
Info
Price
TIER 1
HealthChek™ with Fecal Dx®Profile, Lab 4Dx® Plus and Urinalysis (89369999)
Chem 25 with IDEXX SDMA® Test, IDEXXCBC™, fecal ova and parasites,hookworm, roundworm, whipwormantigen immunoassays, Lab 4Dx® PlusTest, urinalysis
$336.90
TIER 2
Adult Annual with Fecal Dx® Profileand Lab 4Dx® Plus Test (38749999)
Chem 18 with IDEXX SDMA® Test, IDEXXCBC®, fecal ova and parasites, hookworm, roundworm and whipworm antigen immunoassays, Lab 4Dx® Plus Test
$199
TIER 3
Adult Wellness (12729999)
Chem 21 with IDEXX SDMA® Test, IDEXX CBC®
$161.18
Heartworm Test - In House
$45
Fecal Dx® Antigen Panel Add-on—Canine/Feline (51991)
$34.21
Companion Animal Parasite Council (CAPC) Data
https://www.aspca.org/pet-care/animal-poison-control
The AVMA and AAHA discourage the feeding of raw animal-source protein to dogs due to the high risk of illness to both pets and humans. Pathogens found in raw protein diets can be transmitted to the human population by contact with the food, pet, or environmental surfaces.
Neutering is associated with a prolonged life expectancy for both sexes compared to their entire counter parts. This has been reported in multiple studies. In female dogs, neutering reduces or eliminates the risk of pyometra, a potentially life-threatening condition. Neutering is linked to a reduced risk of cancer of reproductive organs and heart disease, but an increased risk of joint disorders and some cancers (lymphoma and hemangiosarcoma) especially in females. [1,2]
Health risks by breed can be found at https://www.akc.org/ under the Health link on each breedinformation page. A handful of large scale publications on breed related mortality are available.
Brachycephalic breeds (French Bulldog, English Bulldog, Pug, and American Bulldog) are predispositions to life-limiting disorders that occur early in life, such as brachycephalic obstructive airway syndrome (BUAS), spinal disease, and dystocia.Brachycephalic breeds should avoid high temperatures, overexertion, and over-conditioning(obesity). Harnesses rather than collars should be used for leash walks. Preemptive surgical intervention to improve upper airway conformation should be recommended before a respiratory crisis occurs.
Deep chested, large breed dogs (Great Danes, Weimaraners, St. Bernards, Irish setters, Gordonsetters…) are predisposed to gastric dilation and volvulus (GDV). Pre-emptive gastropexy should be recommended to reduce the risk of GDV. Feed more than one meal a day and select a dog food with a low fat and oil content.
Chondrodystrophic breeds (Dachshund, Pekinese, Beagle, Lhasa Apso) are predisposed to intervertebral disk disease (IVDD). Avoid over-feeding and obesity. Use a harness rather than a collar for leash walks. Avoid high impact activities like jumping on and off furniture, consider the use of portable pet stairs.
Many breeds are predisposed to congenital heart disease. If a murmur or arrhythmia is detected on annual physical exam, a thoracic radiograph or EKG should be pursued. If these are abnormal, a cardiology referral is recommended. [6, open access journal with helpful diagnostic flow chart]
● Aortic Stenosis: Boxers, Golden Retrievers, Rottweilers, German Shepherds, Newfoundlands
● Pulmonic Stenosis: Boston terriers, Boxers, English Bulldogs, French Bulldogs, BoykinSpaniels, Jack Russell Terriers, Keeshonds, terriers
● Patent Ductus Arteriosus (PDA): Small breed dogs, German Shepherds, Newfoundland
● Ventricular Septal Defect (VSD): English Springer Spaniels
● Renal dysplasia: Alaskan Malamutes, Bedlington Terriers, Chow Chows, Cocker Spaniels,Doberman Pinschers, Keeshonden, Lhasa Apsos, Miniature Schnauzers, NorwegianElkhounds, Samoyeds, Shih Tzus, Soft-coated Wheaten Terriers, and Standard Poodles
o Usually diagnosed via renal ultrasound imaging in juveniles in conjunction with azotemia, isosthenuria.
● Polycystic kidney disease: Beagles, Bull Terriers, Cairn Terriers, and West Highland White Terrier
o Diagnosis is usually made via renal ultrasound in juveniles
● Ductal plate malformations: Boxers
● Portosystemic vascular malformations (Extravascular portosystemic shunts): Small and Toy breeds (Bichon Frise, Border terriers, Maltese, Yorkshire terriers, Cairn terriers, Havanese, Miniature schnauzer, Silky terriers) should be screened for congenital portosystemic vascularmalformations. Large breed dogs (Labrador retrievers, Siberian Husky) occasionally haveintrahepatic portosystemic shunts.
o If a paired serum bile acids test is abnormal, submit a protein C level to CornellCoagulation Laboratory. A protein C less than 70% is consistent with a portosystemicshunt, between 70-99% is in the grey zone, and a value greater than 100% is normal, consistent with microvascular dysplasia. Dogs with a portosystemic shunt should be started on medical management (modified protein diet (Hill’s l/d or Royal Canin Hepatic, lactulose, and gut flora modulation). A CT angiogram will be needed if surgical shunt attenuation will be pursued or to definitively diagnose dogs in the gray zone. No therapy is needed for dogs with microvascular dysplasia.
Vaccination is an efficient and cost-effective form of infectious disease prevention. Most current vaccines are delivered by injection, which provide systemic protection but partial to no protection at mucosal sites. Considering that >90% of pathogens gain access to the body via mucosal sites, using mucosal vaccination to generate protective immunity at mucosal sites could overcome the limitations of current injection-based vaccines in providing front-line protection against pathogen invasion and dissemination (Holmgren J., Czerkinsky C., 2005; Gerdts V. et al., 2006).
Mucosal tissues (e.g. nasal, oral, ocular, rectal, vaginal) cover a large surface of the body. Since many infections are initiated at mucosal sites, it is critical to develop strategies for neutralizing the infectious agent at these surfaces. Mucosal vaccination involves the administration of vaccines at one or more mucosal sites leading to induction of immune responses at the mucosal site of administration, other mucosal sites, and/or systemically.
Immunization involves the delivery of antigens to the mucosal immune system (into
units such as Peyer’s patches in the intestine or the nasal-associated lymphoid tissue in the oropharyngeal cavity). The effector mechanisms for mucosal immune response include the hallmark secretory Immunoglobulin A (SIgA), a protease-resistant antibody and the cell-mediated mucosal immune response. These effectors have been shown to be effective for the clearance of various pathogens including enteric/respiratory viruses and intracellular parasites.
IgA is the first line of defense in the resistance against infection, via inhibiting bacterial
and viral adhesion to epithelial cells and by neutralization of bacterial toxins and virus, both extra- and intracellularly. IgA also eliminates pathogens or antigens via an IgA-mediated excretory pathway where binding to IgA is followed by polyimmunoglobulin receptor-mediated transport of immune complexes. SIgA has an important role in mediating the adaptive (antigen specific) humoral (antibody-based) immune defense at mucosal surfaces.
The majority of mucosal vaccines are administered by the oral and nasal routes.
However, not all routes of administration induce an equivalent immune response in terms of potency and longevity, reflecting differences in the organization and cellular make-up of lymphoid structures in different mucosal tissues (Kantele A., et al., 1998; Czerkinsky C., et al., 2012; Czerkinsky C., Holmgren J., 2010).
For example, oral immunization usually stimulates immune responses in the GI tract in
addition to the oral mucosa and nasal-associated lymphoid tissues (NALT) and mammary glands. Intranasal delivery effectively induces antibody production in salivary glands, the NALT and the bronchus-associated lymphoid tissue (BALT) of the lower respiratory tract, and in the urogenital tract. Rectal immunization elicits a more pronounced immune and antibody response in nasal secretions, tears and the rectal mucosa. Thus, depending on the mucosal sites targeted by different pathogens, the route of immunization needs to be carefully considered (Fujkuyama Y., et al., 2012; Czerkinsky C., Holmgren J., 2010; Saroja C., et al., 2011).
A. Miquel-Clopés et al., Mucosal Vaccines and Technology, Clinical & Experimental Immunology2019
Mucosal Veterinary Vaccines: Comparative Vaccinology
USDA Approved Animal Rabies Vaccines
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7114856/
https://wsava.org/wp-content/uploads/2020/01/WSAVA-Vaccination-Guidelines-2015.pdf